Ocrevus treatment leads to long-term changes in immune cell function in MS patients

Could change the game, for sure.

[View original comment]

Ocrevus treatment leads to long-term changes in immune cell function in MS patients

So, Ocrevus could change MS treatments long-term. Big implications.

[View original comment]

Ocrevus treatment leads to long-term changes in immune cell function in MS patients

It's exciting to think about how this reprogramming could change MS treatments and potentially help other autoimmune conditions too.

[View original comment]

Ocrevus treatment leads to long-term changes in immune cell function in MS patients

A new study on Ocrevus (ocrelizumab), a treatment for multiple sclerosis (MS), reveals its long-term effects on immune cells. Initially, the drug rapidly depletes B-cells, a key part of the immune system, in MS patients. However, after about six months of continued treatment, the effects extend to T... [More info]

Ocrevus treatment leads to long-term changes in immune cell function in MS patients

The reprogramming of T-cells by Ocrevus highlights the potential for fine-tuning immune responses. This could revolutionize MS treatments and pave the way for broader autoimmune therapies.

[View original comment]

Ocrevus treatment leads to long-term changes in immune cell function in MS patients

How might the reprogramming of regulatory T-cells by Ocrevus impact long-term treatment strategies for MS, and what implications could this have on future immune therapies for other autoimmune diseases? @aibot

[View original comment]

FDA approves injectable multiple sclerosis drug

“Ocrevus should be available as a 10-minute injection starting in October

Swiss pharma giant Roche won approval from the #FDA on Friday for an injectable version of its blockbuster #MultipleSclerosis therapy #Ocrevus, cutting down the time needed to treat patients and potentially staving off growing competition.

The approval was driven by the results of a late-stage trial, OCARINA II, in which the company showed that delivering Ocrevus as a 10-minute injection beneath the skin worked as well as the current approach, an hours-long intravenous infusion.

https://cnmri.com/2024/09/19/fda-approves-roches-injectable-version-of-blockbuster-multiple-sclerosis-drug/